Literature DB >> 1702202

Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines.

S Crotta1, S Nicolis, A Ronchi, S Ottolenghi, L Ruzzi, Y Shimada, A R Migliaccio, G Migliaccio.   

Abstract

The transcriptional binding protein NFE-1 (also called GF-1 and Ery-f1) is thought to play a necessary, but not sufficient, role in the regulation of differentiation-related gene expression in a subset of hematopoietic lineages (erythroid, megakaryocytic, and basophil-mast cell). In order to clarify the mechanism which underlies the lineage-specificity of the NFE-1 expression, as well as the relationship between the expression of this factor and growth factor responsiveness, we have evaluated the capacity of erythropoietin (Epo)-, granulomonocytic (GM)-colony stimulating factor (CSF)-, and granulocyte (G)-CSF-dependent subclones derived from the interleukin 3 (IL-3)-dependent cell line 32D, to express 1) NFE-1 mRNA, 2) NFE-1-related nuclear proteins, and 3) chloramphenicol acetyl transferase (CAT) activity when transfected with a CAT gene under the control of NFE-1 cognate sequences. NFE-1 mRNA was found to be expressed not only in cells with mast cell (IL-3-dependent 32D) and erythroid (Epo-dependent 32D Epo1) phenotypes, but also in cells with predominantly granulocyte/macrophage properties, such as the GM-CSF- (early myelomonocytic) and G-CSF- (myelocytic) dependent subclones of 32D. However, a gradient of expression, correlating with the lineage, the stage of differentiation, and the growth factor responsiveness of the cell lines, was found among the different subclones: Epo greater than or equal to IL-3 greater than GM-CSF greater than G-CSF. Binding experiments demonstrated NFE-1 activity in all cell lines except the G-CSF-dependent line. Function of the NFE-1 protein was assessed by the expression of the CAT gene linked to the SV40 promoter and a mutant (-175 T----C) HPFH gamma-globin promoter. High level CAT expression was seen only in the Epo1 cells although low level expression was also seen in the parent 32D. These results demonstrate that the specificity of the expression of NFE-1 for the erythroid--megakaryocytic--mast cell lineages is obtained by progressive inactivation of its expression in alternative lineages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702202      PMCID: PMC332743          DOI: 10.1093/nar/18.23.6863

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  40 in total

1.  In vitro induction of continuous acute promyelocytic leukemia cell lines by Friend or Abelson murine leukemia virus.

Authors:  J S Greenberger; P B Davisson; P J Gans; W C Moloney
Journal:  Blood       Date:  1979-05       Impact factor: 22.113

2.  GATAAG; a cis-control region binding an erythroid-specific nuclear factor with a role in globin and non-globin gene expression.

Authors:  M Plumb; J Frampton; H Wainwright; M Walker; K Macleod; G Goodwin; P Harrison
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

3.  The effects of HPFH mutations in the human gamma-globin promoter on binding of ubiquitous and erythroid specific nuclear factors.

Authors:  R Mantovani; N Malgaretti; S Nicolis; A Ronchi; B Giglioni; S Ottolenghi
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

4.  Selection of lineage-restricted cell lines immortalized at different stages of hematopoietic differentiation from the murine cell line 32 D.

Authors:  G Migliaccio; A R Migliaccio; V Broudy; B Kreider; G Rovera; J W Adamson
Journal:  Prog Clin Biol Res       Date:  1989

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  A simple phase-extraction assay for chloramphenicol acyltransferase activity.

Authors:  B Seed; J Y Sheen
Journal:  Gene       Date:  1988-07-30       Impact factor: 3.688

7.  A protein factor binding to an octamer motif in the gamma-globin promoter disappears upon induction of differentiation and hemoglobin synthesis in K562 cells.

Authors:  R Mantovani; N Malgaretti; B Giglioni; P Comi; N Cappellini; S Nicolis; S Ottolenghi
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

8.  Increased erythroid-specific expression of a mutated HPFH gamma-globin promoter requires the erythroid factor NFE-1.

Authors:  S Nicolis; A Ronchi; N Malgaretti; R Mantovani; B Giglioni; S Ottolenghi
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

9.  Nucleosome disruption precedes transcription and is largely limited to the transcribed domain of globin genes in murine erythroleukemia cells.

Authors:  R B Cohen; M Sheffery
Journal:  J Mol Biol       Date:  1985-03-05       Impact factor: 5.469

10.  Cis- and trans-acting elements involved in the regulation of the erythroid promoter of the human porphobilinogen deaminase gene.

Authors:  V Mignotte; J F Eleouet; N Raich; P H Romeo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

View more
  17 in total

1.  An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice.

Authors:  M A McDevitt; Y Fujiwara; R A Shivdasani; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors.

Authors:  N M Sposi; L I Zon; A Carè; M Valtieri; U Testa; M Gabbianelli; G Mariani; L Bottero; C Mather; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface.

Authors:  A R Migliaccio; G Migliaccio; A D'Andrea; M Baiocchi; S Crotta; S Nicolis; S Ottolenghi; J W Adamson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  GATA transcription factors associate with a novel class of nuclear bodies in erythroblasts and megakaryocytes.

Authors:  A G Elefanty; M Antoniou; N Custodio; M Carmo-Fonseca; F G Grosveld
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

5.  The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line.

Authors:  J E Visvader; M Crossley; J Hill; S H Orkin; J M Adams
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

6.  Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene.

Authors:  B L Kreider; S H Orkin; J N Ihle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

7.  DNA-binding specificity of GATA family transcription factors.

Authors:  M Merika; S H Orkin
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

8.  An erythroid specific enhancer upstream to the gene encoding the cell-type specific transcription factor GATA-1.

Authors:  S Nicolis; C Bertini; A Ronchi; S Crotta; L Lanfranco; E Moroni; B Giglioni; S Ottolenghi
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

9.  Activation of the beta-globin locus control region precedes commitment to the erythroid lineage.

Authors:  G Jiménez; S D Griffiths; A M Ford; M F Greaves; T Enver
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  A homozygous missense arginine to histidine substitution at position 482 of the beta-galactosidase in an Italian infantile GM1-gangliosidosis patient.

Authors:  G Mosna; S Fattore; G Tubiello; S Brocca; M Trubia; E Gianazza; R Gatti; C Danesino; A Minelli; M Piantanida
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.